Markets
PLX

Protalix BioTherapeutics (PLX) Jumps: Stock Rises 9%

Protalix BioTherapeutics, Inc PLX was a big mover last session, as the company saw its shares rise 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $0.56-$0.63 in the past one-month time frame, witnessed a sharp increase yesterday.

The company has seen no estimate revisions over the past one month, and the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Protalix currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Protalix BioTherapeutics, Inc. Price and Consensus

Protalix BioTherapeutics, Inc. Price and Consensus | Protalix BioTherapeutics, Inc. Quote

A better ranked stock in the Medical - Biomedical and Genetics industry is Axovant Sciences Ltd.AXON which carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .

Is PLX going up? Or down? Predict to see what others think: Up or Down

The Hottest Tech Mega-Trend of All

Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce ""the world's first trillionaires,"" but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Protalix BioTherapeutics, Inc. (PLX): Free Stock Analysis Report

Axovant Sciences Ltd. (AXON): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

PLX

Other Topics

Investing Stocks